TWi Biotechnology announced on the 5th that its global Phase 2/3 trial, "EBShield," for the treatment of Epidermolysis Bullosa Simplex (EBS)—a rare genetic "butterfly skin" disease—successfully passed its interim analysis.

• DSMB Recommendation: The Data Safety Monitoring Board (DSMB) confirmed no safety concerns and recommended the trial proceed to its full enrollment target of 80 subjects. The interim analysis was conducted after 60 subjects completed the 8-week double-blind Part A phase.
• Regulatory & Commercial Status: AC-203 is a First-in-Class topical anti-inflammatory. It has secured Orphan Drug Designation in the U.S., EU, and Taiwan, along with Fast Track and Rare Pediatric Disease designations from the FDA.
• Licensing Strategy: General Manager Tsai Cheng-en noted that licensing deals have already been completed for Greater China, Japan, and South Korea. With the positive interim data, the company is now accelerating licensing negotiations for the U.S. and European markets.
• Other Pipeline Updates: The company is adjusting the trial design for NORA520 (Postpartum Depression) due to low blood concentration issues in Phase 2 and plans to move AC-1101 into a Phase 2a trial for Alopecia Areata.

Resource: 安成生技AC-203期中分析過關 DSMB建議續收80例、加速全球授權布局